T AND TN PANCARCINOMA MARKERS - AUTOANTIGENIC ADHESION MOLECULES IN PATHOGENESIS, PREBIOPSY CARCINOMA-DETECTION, AND LONG-TERM BREAST-CARCINOMA IMMUNOTHERAPY

被引:87
作者
SPRINGER, GF
机构
[1] CHICAGO MED SCH, DEPT SURG, HEATHER M BLIGH CANC RES LABS, N CHICAGO, IL 60064 USA
[2] NORTHWESTERN UNIV, CTR CANC, CHICAGO, IL 60611 USA
来源
CRITICAL REVIEWS IN ONCOGENESIS | 1995年 / 6卷 / 01期
关键词
T TN PANCARCINOMA ANTIGENS; AUTOIMMUNE RESPONSES TO CARCINOMA T TN ANTIGENS; PRECLINICAL CARCINOMA DETECTION BY T ASSAYS; T AND TN EPITOPES IN CARCINOMA PATHOGENESIS; T TN EPITOPES IN CELL ADHESION; DELAYED-TYPE SKIN HYPERSENSITIVITY TO T TN ANTIGEN; HUMORAL RESPONSE TO T ANTIGEN; EFFICACIOUS T TN ANTIGEN CARCINOMA VACCINE;
D O I
10.1615/CritRevOncog.v6.i1.50
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Physical and chemical nature of the T and Tn pancarcinoma [CA] glycopeptide epitopes [EPs], which are immediate precursors of the blood group MN EPs, and their role in CA pathogenesis and in clinical disease are discussed. T/Tn are immuno-occluded in non-CA diseased and in healthy tissues. Well-differentiated CAs usually express a higher proportion of T than Tn EPs, while Tn predominates in poorly differentiated primary CAs. Measurement of density of T and Tn EP expression on primary breast CA permits disease prognostication. CA-T and -Tn are cell adhesion molecules involved not only in invasion but also in metastasis. Immunological methods readily detect in vivo autoimmune responses to CA-T and -Tn EPs in about 90% of all CA patients from incipience and throughout. Everyone has preexisting anti-T and anti-Tn antibodies [Abs] induced by the intestinal flora. T/anti-T immunoassays are highly efficient in detection of incipient and clinically overt CAs and, importantly, predicted CA in 77% of the patients, months to many years before their biopsy/X-ray turned positive; there were no false immune predictions of CA. Since 1974, we use human O MN red cell-derived T/Tn glycoprotein vaccine plus adjuvants successfully in safe, specific, effective, long-term, active immunotherapy against recurrence of advanced breast CA pTNM Stages IV, III, and II.
引用
收藏
页码:57 / 85
页数:29
相关论文
共 238 条
[1]  
AGGELER J, 1991, J CELL SCI, V99, P407
[2]  
ALLER CT, 1993, J IMMUNOL, V150, pA143
[3]   BLOOD GROUP-LIKE ACTIVITY RELEASED BY HUMAN MAMMARY-CARCINOMA CELLS IN CULTURE [J].
ANGLIN, JH ;
LERNER, MP ;
NORDQUIST, RE .
NATURE, 1977, 269 (5625) :254-255
[4]   CELLULAR MUCINS - TARGETS FOR IMMUNOTHERAPY [J].
APOSTOLOPOULOS, V ;
MCKENZIE, IFC .
CRITICAL REVIEWS IN IMMUNOLOGY, 1994, 14 (3-4) :293-309
[5]  
ASHALL F, 1982, LANCET, V2, P1
[6]  
AVICHEZER D, 1995, UNPUB IMMUNOREACTIVI
[7]  
BAILLY P, 1985, GLYCOCONJUGATE J, V2, P401
[8]   IMMUNOCHEMICAL STUDIES ON THE COMBINING SITES OF FORSSMAN HAPTEN REACTIVE HEMAGGLUTININS FROM DOLICHOS-BIFLORUS, HELIX-POMATIA, AND WISTARIA-FLORIBUNDA [J].
BAKER, DA ;
SUGII, S ;
KABAT, EA ;
RATCLIFFE, RM ;
HERMENTIN, P ;
LEMIEUX, RU .
BIOCHEMISTRY, 1983, 22 (11) :2741-2750
[9]  
BARR N, 1989, CANCER-AM CANCER SOC, V64, P834, DOI 10.1002/1097-0142(19890815)64:4<834::AID-CNCR2820640413>3.0.CO
[10]  
2-A